- Home
- TEAF vs MDWD Comparison
TEAF vs MDWD Comparison
Compare TEAF & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- MDWD
- Stock Information
- Founded
- TEAF 2017
- MDWD 2000
- Country
- TEAF United States
- MDWD Israel
- Employees
- TEAF N/A
- MDWD N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- TEAF Finance
- MDWD Health Care
- Exchange
- TEAF Nasdaq
- MDWD Nasdaq
- Market Cap
- TEAF 174.8M
- MDWD 172.6M
- IPO Year
- TEAF N/A
- MDWD 2014
- Fundamental
- Price
- TEAF $12.51
- MDWD $16.00
- Analyst Decision
- TEAF
- MDWD Strong Buy
- Analyst Count
- TEAF 0
- MDWD 1
- Target Price
- TEAF N/A
- MDWD $28.00
- AVG Volume (30 Days)
- TEAF 56.1K
- MDWD 42.5K
- Earning Date
- TEAF 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- TEAF 9.20%
- MDWD N/A
- EPS Growth
- TEAF N/A
- MDWD N/A
- EPS
- TEAF N/A
- MDWD N/A
- Revenue
- TEAF N/A
- MDWD $20,141,000.00
- Revenue This Year
- TEAF N/A
- MDWD $30.16
- Revenue Next Year
- TEAF N/A
- MDWD $18.44
- P/E Ratio
- TEAF N/A
- MDWD N/A
- Revenue Growth
- TEAF N/A
- MDWD N/A
- 52 Week Low
- TEAF $11.11
- MDWD $8.22
- 52 Week High
- TEAF $13.30
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- TEAF 33.68
- MDWD 36.64
- Support Level
- TEAF $12.57
- MDWD $16.66
- Resistance Level
- TEAF $12.64
- MDWD $17.63
- Average True Range (ATR)
- TEAF 0.14
- MDWD 0.69
- MACD
- TEAF -0.04
- MDWD -0.20
- Stochastic Oscillator
- TEAF 7.67
- MDWD 9.02
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.